FEB 2 6 2001 FEB 1N.

Express Mail No.: EL 501 637 234 US

P#-5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Soff et al.

RECEIVED

MAR 0 > 2001

Application No.: 09/500,397

Group Art Unit: 1643

TECH CENTER 1600/2900

Filed: February 8, 2000

Examiner: To Be Assigned

For:

METHODS AND COMPOSITIONS

Attorney Docket No.: 10561-005

FOR GENERATING ANGIOSTATIN

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97 & §1.56

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references AB-CZ listed on the attached revised form PTO-1449.

Identification of the listed references is not to be construed an admission of the Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith several pages of a "revised form PTO 1449" entitled "List of References Cited."

Copies of references AB to CZ are believed to be of record in parent U.S. Application No. 08/991,761 filed on December 16, 1997 and U.S. Application No. 08/710,305 filed on September 17, 1996 which are relied upon for a filing date under 35 U.S.C. § 120. Accordingly, pursuant to 37 C.F.R. § 1.98(d), Applicants are not submitting additional copies of these references. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of this application.

Pursuant to 37 C.F.R. § 1.97(b), since this Supplemental Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits no fee is believed to be due. However, if a fee is required please charge the fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: February 26, 2001

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090

Enclosures